Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: Janice Shell who wrote (3792)	11/4/1999 11:04:00 AM
From: Hogger	Read Replies (1) \| Respond to of 4028

ragingbull.com Thursday November 4, 8:02 am Eastern Time Company Press Release CYGS - PCCA Joint Effort to Provide Customized Pharmacogenomic Products HOUSTON--(BUSINESS WIRE)--Nov. 4, 1999--Cryogenic Solutions Inc. (OTCBB:CYGS - news) has joined with Professional Compounding Centers Of America Inc. (PCCA) to form PharmaGenix LLC. The CYGS-PCCA cooperative corporate enterprise will link traditional pharmacology with molecular biology to provide personalized healthcare products for the 21st Century. CYGS will license its proprietary single stranded DNA intracellular expression vector (ssDNAev) technology to PharmaGenix(TM) for use by compounding pharmacists as an excipient constituent for the preparation of novel nutritional and cosmetic products. Compounding Pharmacists provide customized multi-ingredient combinations of herbals, chemicals, and naturally occurring biological components according to physicians' prescriptions where these compounds are not available through mass-market pharmaceutical companies. PCCA represents some 2500 member compounding pharmacies servicing over 100,000 physicians and veterinarians who customize prescriptions for their patients. Historically, pharmacists have combined various components into products that provided symptomatic relief or temporary control of physical ailments. Today however, breakthroughs in molecular biology offer new alternatives. Biotechnology has identified biochemical molecules called oligodeoxyribonucleotides (ODNs) with the potential to permanently relieve many complaints. The protocols, apparatus, and instruments are now available which enable a compounding pharmacist to create products composed of naturally occurring biological components such as DNA, RNA, and various proteins or enzymes useful in preventive measures. The CYGS expression vector promises to be useful in enabling the new technology by delivering ODNs to the targeted cells. These scientific breakthroughs herald an increasing emphasis moving away from simply relieving symptoms to actually treating the disease. The role of PharmaGenix(TM) is to support compounding pharmacists, patients, and physicians and assist in the utilization of the new technologies that are emerging in the evolution of customized healthcare products. PCCA invited Charles Conrad, MD, inventor of the ODN expression vector, to present a program outlining the practical applications of pharmacogenomics on October 16th. The special presentation was included in the comprehensive seminar series that PCCA regularly provides for member pharmacists. This and subsequent training will enable compounding pharmacists to upgrade their knowledge and equipment to effectively participate in the promising new technologies. An integral part of the PharmaGenix(TM) services will be development and presentation of educational programs, materials, and web offerings to introduce the concepts of pharmacogenomics to students, pharmacists and physicians. The programs will include presentations at professional meetings and seminars; articles in the PCCA journal, The Apothegram; and other printed material, videos, CD-ROMs, and software. In addition, a comprehensive continuing education presence will be maintained on the web at www.pharmagenix.com, currently under construction. There is a growing population of physicians with knowledge of molecular biology and of specific antisense ODN's. If the historical pattern of adoption of new medical technology is any guide, ever increasing numbers of physicians can be expected to utilize specific ODN's to assist their patients. PharmaGenix(TM) services and products will enable the compounding pharmacists and the physicians, veterinarians and other health care providers they serve to distribute antisense products. The new entry point defined by this process will also serve the commercial interests of the more than 600 US Patent owners of antisense ODNs that may elect to work with PharmaGenix(TM) to provide scientific information to physicians who may wish to prescribe the use of specific ODN's. -------------------------------------------------------------------------------- Contact: Cryogenic Solutions Inc., Houston Dell Gibson, 713/780-1399